Insulin lispro (Humalog), the first marketed insulin analogue: Indications, contraindications and need for further study

Puttagunta, Anuradha L.; Toth, Ellen L.
February 1998
CMAJ: Canadian Medical Association Journal;02/24/98, Vol. 158 Issue 4, p506
Academic Journal
Presents research which reviewed the available literature on the new insulin analogue insulin lispro. Information on insulin lispro's efficacy, indications for use and contraindications; Data sources; Study selection; Therapeutic challenge of diabetic patients; Benefits of insulin lispro compared with human insulin; When insulin lispro is most useful; Use of insulin pumps; Need for further study.


Related Articles

  • Insulin Lispro: A Fast-Acting Insulin Analog. Noble, Sara L.; Johnston, Elizabeth; Walton, Bill // American Family Physician;1/15/1998, Vol. 57 Issue 2, p279 

    States that research has established the importance of maintaining blood glucose levels near normal in patients with type 1 diabetes mellitus. What short-acting insulin analogs are designed to do; Comparison between regular human insulin and analog insulin lispro; When insulin lispro begins to...

  • Using Insulin Lispro.  // American Family Physician;1/15/1998, Vol. 57 Issue 2, p289 

    Provides information on how to use insulin lispro in the treatment of patients with type 1 diabetes mellitus. Definition of what insulin lispro is; How it can control blood sugar levels; When and how this medication is administered.

  • Effectiveness of Human Ultralente Versus NPH Insulin in Providing Basal Insulin Replacement for an Insulin Lispro Multiple Daily Injection Regimen. Zinman, Bernard; Ross, Stuart; Campos, Robert V.; Strack, Thomas // Diabetes Care;Apr99, Vol. 22 Issue 4, p603 

    Presents information on a study that compared human ultralente insulin with human NPH insulin as basal insulin replacement in patients who use insulin lispo before meals. Research design and methods; Results; Conclusions.

  • Efficacy and Safety of HOE 901 Versus NPH Insulin in Patients With Type 1 Diabetes. Pieber, Thomas R.; Eugene-Jolchine, Irene; Derobert, Eric // Diabetes Care;Feb2000, Vol. 23 Issue 2, p157 

    Presents information on a study which compared the effect of the long-acting insulin analog HOE 901 with NPH insulin regarding glycemic control in patients with type 1 diabetes. Research designs and methods; Effect of insulin analogs on fasting plasma glucose; Indicators of glycemic control;...

  • Insulin degludec and insulin degludec/insulin aspart: a guide to their use in diabetes mellitus. Keating, Gillian // Drugs & Therapy Perspectives;Oct2013, Vol. 29 Issue 10, p297 

    Insulin degludec (Tresiba) is an ultra-long-acting insulin analogue that is also available as a coformulation (Ryzodeg) with rapid-acting insulin aspart. Insulin degludec achieves similar glycaemic control to that seen with insulin glargine in patients with type 1 or 2 diabetes, but with a lower...

  • Efficacy and Safety of Insulin Glargine Compared to Other Interventions in Younger and Older Adults: A Pooled Analysis of Nine Open-Label, Randomized Controlled Trials in Patients with Type 2 Diabetes. Pandya, Naushira; DiGenio, Andres; Gao, Ling; Patel, Meenakshi // Drugs & Aging;2013, Vol. 30 Issue 6, p429 

    Objective: Elderly patients with type 2 diabetes mellitus (T2DM) present therapeutic challenges related to co-morbidities, treatment adherence, and safety. This study examines the efficacy and safety of insulin glargine compared to other glucose-lowering interventions in younger and older...

  • Use and Out-of-Pocket Costs of Insulin for Type 2 Diabetes Mellitus From 2000 Through 2010. Lipska, Kasia J.; Ross, Joseph S.; Van Houten, Holly K.; Beran, David; Yudkin, John S.; Shah, Nilay D. // JAMA: Journal of the American Medical Association;6/11/2014, Vol. 311 Issue 22, p2331 

    The article discusses research which examined the trends in insulin use, out-of-pocket expenditures, and severe hypoglycemic events among privately insured type-2 diabetic adults in the U.S. from 2000 through 2010. Topics covered include the increase in the use of insulin among patients, the...

  • Early therapy with basal insulin does not reduce cardiovascular outcomes in dysglycemic patients. Sobieraj, Diana // Formulary;Dec2012, Vol. 47 Issue 12, p417 

    The article discusses research which was reported in the article "Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia" and was published in the "New England Journal of Medicine" The research found that early therapy with basal insulin does not reduce cardiovascular outcomes...

  • Needles away. Boyce, Nell // New Scientist;06/12/99, Vol. 162 Issue 2190, p17 

    Focuses on a new insulin drug that may render daily injections obsolete. Side effects of traditional immunosuppressive drugs used to try and create healthy insulin-producing cells; How the infusion of islet cells coupled with the new antibody that blocks receptor CD145 in diabetic monkeys led...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics